Entrectinib (RozlytrekTM), which contains the indazole moiety, is also a tyrosine kinase inhibitor for the treatment of ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. Here, ROS1 is linked to non-small cell lung carcinoma.